The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
about
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.Management of Potential Long-Term Toxicities in Breast Cancer Patients.Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategies.
P2860
The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The optimal duration of adjuva ...... h what drugs and for how long?
@en
type
label
The optimal duration of adjuva ...... h what drugs and for how long?
@en
prefLabel
The optimal duration of adjuva ...... h what drugs and for how long?
@en
P2860
P1476
The optimal duration of adjuva ...... h what drugs and for how long?
@en
P2093
Belinda Yeo
Stephen R D Johnston
P2860
P2888
P356
10.1007/S11912-013-0358-9
P577
2014-01-01T00:00:00Z
P6179
1036886403